Finance

Gilgamesh Withdraws Patent Challenge After AbbVie Deal

Gilgamesh Pharmaceuticals pulled its Post-Grant Review against Enveric's '276 patent in November 2025 after AbbVie filed to withdraw the petition. Enveric says the core claims remain uncontested, reducing near-term IP risk and potentially accelerating licensing discussions tied to GM-2505.

📅 February 25, 2026
⏱️ 2 min read
Gilgamesh Withdraws Patent Challenge After AbbVie Deal

Key Takeaways

  • Gilgamesh withdrew its Post-Grant Review against Enveric's '276 patent in November 2025 after AbbVie requested withdrawal.
  • '276 patent covers halogenated psilocybin derivatives linked to Enveric's GM-2505 (bretisilocin).
  • AbbVie agreed to acquire Gilgamesh's bretisilocin asset for up to $1.2 billion in 2025.
  • Enveric says withdrawal resolves the proceeding and leaves the patent unchallenged, reducing IP risk.
  • ENVB stock moved lower in premarket trading on the news (down about 1.45%).

People Involved

  • No specific individuals mentioned

Entities Involved

  • Enveric Biosciences Inc (ENVB) Owner of GM-2505 program and issuer of the contested '276 patent
  • AbbVie Inc (ABBV) Buyer of Gilgamesh's bretisilocin asset; requested withdrawal of the petition
  • Gilgamesh Pharmaceuticals Inc Asset owner; participant in the PGR and in the AbbVie deal

MarketMoodz Analysis

For investors, the withdrawal removes a persistent IP risk around GM-2505 and the EB-003 program, potentially clearing the path for licensing discussions and boosting partner interest as a pharma acquirer shows appetite for psychedelic-based assets. The AbbVie-Gilgamesh deal backdrop adds strategic value to Enveric's IP moat by aligning major pharma with the asset class.

Historically, post-grant challenges in biotech/IP can delay collaborations and deprioritize licensing talks. The absence of ongoing challenges to the '276 patent may support a higher near-term valuation for Enveric, but progress on EB-003 data and regulatory milestones will determine the ultimate licensing trajectory and deal outcomes.

Watch for EB-003 clinical updates, news on formal licensing talks or partnerships tied to the '276 portfolio, and any further PTAB docket activity or company disclosures that could alter the IP-risk profile.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial